GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure
Frank Vinluan / medcitynews - GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. T…
AI Summary: The FDA approved GSK’s new chronic hepatitis B therapy, a first‑of‑its‑kind agent described as offering the potential for a functional cure. Regulators cleared the drug after reviewing pivotal data, and stakeholders are already recalibrating clinical pathways for HBV care — because treating a chronic infection like it might actually end is a novel problem to have.
Related Stories
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 5 months
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 5 months
Denali drug receives accelerated approval for rare CNS indication / 6 months
FDA approves Merck’s once‑daily two‑drug HIV pill, shaking up market / 5 months
FDA clears first oral cholesterol pill to compete with injections / 3 months
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 6 months
FDA clears first once‑weekly basal insulin for Type 2 diabetes / 6 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Hearing Loss, Venture Capital, Behavioral Health and look for the RSS link.
StackHealth Time Machine